Impact of evolocumab on periprocedural microvascular damage in patients undergoing percutaneous coronary intervention (PCI)

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2018
INTERVENTION: Evolocumab standard of care CONDITION: stable coronary artery disease PRIMARY OUTCOME: Index of microvascular resistance after PCI INCLUSION CRITERIA: (1) Patients aged 20 to 85 years at the time of informed consent. (2) Patients with stable coronary artery disease who are planned to undergo PCI. (3) Patients with high LDL‐C levels after at least 2‐week treatment of high‐dose statin (4) Patients who are capable of providing written consent.
Epistemonikos ID: 5d33bc1b132b913f7b1b11c364a2af91d4d6e385
First added on: Aug 24, 2024